{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:52Z","timestamp":1791575392449,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"High-quality Specialized of the Joint Logistic Support Force","award":["41C41B27"],"award-info":[{"award-number":["41C41B27"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Primary bone marrow lymphoma (PBML) is a rare lymphoma with a poor prognosis, characterized by tumor origin restricted to the bone marrow. Diffuse large B-cell lymphoma (DLBCL) is its most common subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report a case of a 48-year-old female with refractory non-germinal center DLBCL originating in the bone marrow, accompanied by p53 overexpression, complex karyotype, and hemophagocytic lymphohistiocytosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Given the aforementioned adverse genetic features, together with primary platelet poor graft function following allogeneic hematopoietic stem cell transplantation (allo-HSCT), mixed infections, severe acute intestinal graft-versus-host disease (GVHD), and progressive bone marrow stromal necrosis, the patient was diagnosed with multifactorial post-transplant poor graft function with bone marrow microenvironment injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received induction chemotherapy and achieved complete remission, followed by autologous-hematopoietic stem cell transplantation (autoHSCT) for consolidation. After relapse within 3 months, salvage therapy and subsequent allogeneic-hematopoietic stem cell transplantation were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Despite intensive supportive therapy, the patient died from massive gastrointestinal bleeding. A literature review identified this as a rare case of PBML with primary platelet Poor graft function and mixed infections post-allo-HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights the treatment challenges and extremely poor prognosis in ultrahigh-risk PBML with adverse genetic features and severe post-transplant complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050987","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:00:21Z","timestamp":1791572421000},"page":"e50987","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Relapsed\/refractory PBML complicated with failed platelet implantation and mixed infection after allo-HSCT"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3615-4098","authenticated-orcid":false,"given":"Ying","family":"He","sequence":"first","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Hematological Disease"},{"name":"Branch of National Clinical Research Center for Hematological Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Hematological Disease"},{"name":"Branch of National Clinical Research Center for Hematological Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Hematological Disease"},{"name":"Branch of National Clinical Research Center for Hematological Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Hematological Disease"},{"name":"Branch of National Clinical Research Center for Hematological Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-266X","authenticated-orcid":false,"given":"Hai","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Hematological Disease"},{"name":"Branch of National Clinical Research Center for Hematological Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/PAS.0b013e31823ea106","article-title":"Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas.","volume":"36","author":"Martinez","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/CMAR.S187522","article-title":"Clinical features and prognostic factors of primary bone marrow lymphoma.","volume":"11","author":"Wang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R3-20261009","first-page":"561","article-title":"Large B-cell lymphoma presenting primarily in bone marrow is frequently associated with haemophagocytic lymphohistiocytosis and has distinct cytogenetic features.","volume":"52","author":"Yang","year":"2020","journal-title":"Pathology (Phila)"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-010-1129-4","article-title":"Primary bone marrow diffuse large B cell lymphoma: a case series and review.","volume":"90","author":"Chang","year":"2011","journal-title":"Ann Hematol"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"957063","DOI":"10.1155\/2012\/957063","article-title":"Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells.","volume":"2012","author":"Kazama","year":"2012","journal-title":"Case Rep Med"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3343\/alm.2017.37.6.544","article-title":"A case of primary bone marrow diffuse large B-cell lymphoma presenting with fibrillar projections and hemophagocytic lymphohistiocytosis.","volume":"37","author":"Kim","year":"2017","journal-title":"Ann Lab Med"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1309\/2GW5W7KQBXF6LFAW","article-title":"Diffuse large B-cell lymphoma initially manifesting in the bone marrow.","volume":"127","author":"Kajiura","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1002\/cam4.1669","article-title":"Primary bone marrow lymphoma: a hematological emergency in adults with fever of unknown origin.","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/his.14124","article-title":"Aggressive B-cell lymphomas with a primary bone marrow presentation.","volume":"77","author":"Zam\u00f2","year":"2020","journal-title":"Histopathology"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ctrv.2015.02.001","article-title":"Primary and secondary bone lymphomas.","volume":"41","author":"Messina","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semdp.2014.01.004","article-title":"Primary lymphoma of bone: a review.","volume":"31","author":"Bhagavathi","year":"2014","journal-title":"Semin Diagn Pathol"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"2040620720948743","DOI":"10.1177\/2040620720948743","article-title":"Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.","volume":"11","author":"Chen","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms.","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee.","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"2324709620982765","DOI":"10.1177\/2324709620982765","article-title":"Aggressive diffuse intermediate size B-Cell lymphoma with P53 mutation presented as primary bone marrow lymphoma.","volume":"8","author":"Chen","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis.","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma.","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R19-20261009","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2023-190639","article-title":"Determinants of response to anti CD-19 CAR-T cells for diffuse large b-cell lymphoma in pre-treatment peripheral blood mononuclear cells using single-cell RNA-Seq.","volume":"142","author":"Ram","year":"2023","journal-title":"Blood"},{"issue":"Supple 1","key":"R20-20261009","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1182\/blood-2025-5882","article-title":"Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL.","volume":"146","author":"Spiegel","year":"2025","journal-title":"Blood"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.","volume":"145","author":"Chavez","year":"2025","journal-title":"Blood"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12703\/r\/12-4","article-title":"Recent advances in graft-versus-host disease.","volume":"12","author":"Flinn","year":"2023","journal-title":"Fac Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:00:23Z","timestamp":1791572423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050987"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":21,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050987","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}